$101.48
0.55% yesterday
Nasdaq, Sep 16, 10:00 pm CET

Illumina Stock price

$101.48
+0.95 0.95% 1M
+15.80 18.44% 6M
-32.15 24.06% YTD
-28.04 21.65% 1Y
-93.26 47.89% 3Y
-212.70 67.70% 5Y
-98.53 49.26% 10Y
+94.94 1,451.11% 20Y
Nasdaq, Closing price Tue, Sep 16 2025
+0.56 0.55%

Key metrics

Basic
Market capitalization
$15.6b
Enterprise Value
$16.4b
Net debt
$836.0m
Cash
$1.2b
Shares outstanding
154.0m
Valuation (TTM | estimate)
P/E
12.7 | 22.0
P/S
3.6 | 3.6
EV/Sales
3.8 | 3.8
EV/FCF
15.9
P/B
6.9
Financial Health
Equity Ratio
37.7%
Return on Equity
-51.5%
ROCE
19.1%
ROIC
18.0%
Debt/Equity
0.9
Financials (TTM | estimate)
Revenue
$4.3b | $4.3b
EBITDA
$1.2b | $1.2b
EBIT
$882.0m | $963.2m
Net Income
$1.3b | $709.9m
Free Cash Flow
$1.0b
Growth (TTM | estimate)
Revenue
-3.3% | -0.6%
EBITDA
72.9% | 75.6%
EBIT
266.0% | 45.7%
Net Income
141.3% | 158.1%
Free Cash Flow
188.8%
Margin (TTM | estimate)
Gross
66.6%
EBITDA
27.1% | 26.8%
EBIT
20.6%
Net
29.4% | 16.3%
Free Cash Flow
24.1%
More
EPS
$8.0
FCF per Share
$6.7
Short interest
7.3%
Employees
9k
Rev per Employee
$490.0k
Show more

Is Illumina a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,016 stocks worldwide.

Illumina Stock Analysis

Unlock Scores for Free

Analyst Opinions

30 Analysts have issued a Illumina forecast:

14x Buy
47%
13x Hold
43%
3x Sell
10%

Analyst Opinions

30 Analysts have issued a Illumina forecast:

Buy
47%
Hold
43%
Sell
10%

Financial data from Illumina

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
4,284 4,284
3% 3%
100%
- Direct Costs 1,433 1,433
15% 15%
33%
2,851 2,851
4% 4%
67%
- Selling and Administrative Expenses 977 977
19% 19%
23%
- Research and Development Expense 992 992
24% 24%
23%
1,160 1,160
73% 73%
27%
- Depreciation and Amortization 278 278
35% 35%
6%
EBIT (Operating Income) EBIT 882 882
266% 266%
21%
Net Profit 1,258 1,258
141% 141%
29%

In millions USD.

Don't miss a Thing! We will send you all news about Illumina directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Illumina Stock News

Neutral
PRNewsWire
14 days ago
Illumina Protein Prep can measure 9500 unique human protein targets, offering new insights into protein biology to fuel novel discovery for treatment of disease Following early access program, customers commend scale, high consistency, and easy sample to insights workflow Launch follows Illumina's announcement of agreement to acquire SomaLogic SAN DIEGO , Sept. 3, 2025 /PRNewswire/ -- Illumina ...
Negative
Seeking Alpha
20 days ago
mRNA vaccine companies are overhyped post-pandemic, facing scientific, operational, and regulatory headwinds that limit long-term investment appeal. Scientific and business risks, including delivery challenges and limited efficacy for cancer and infectious diseases, make mRNA-focused biotechs unattractive compared to broader biotech opportunities. Investors seeking exposure should consider 'pic...
Neutral
MCAP MediaWire
about one month ago
Seasoned healthcare CFO with senior experience in capital markets and financial operations across private and publicly traded companies to lead BioStem's financial team POMPANO BEACH, FL, August 14, 2025 – PRISM MediaWire – BioStem Technologies, Inc.
More Illumina News

Company Profile

Illumina, Inc. engages in the development, manufacturing, and marketing of life science tools and integrated systems for large-scale analysis of genetic variation and function. It operates through Core Illumina segment, which serves customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. The firm's products include microarray scanners, sequencing reagents, and onsite training selector. Its services include sequencing and microarray services; proactive instrument monitoring; and instrument services, training, and consulting. The company was founded by David R. Walt, John R. Stuelpnagel, Anthony W. Czarnik, Lawrence A. Bock, and Mark S. Chee in April 1998 and is headquartered in San Diego, CA.

Head office United States
CEO Jacob Thaysen
Employees 9,000
Founded 1998
Website www.illumina.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today